Given the differences in methods for determination of HPV status in patients with squamous cell cancers in the literature, we developed this study to evaluate and compare tumor expression of p16/HPV16 using three different methods and its association with clinical outcome in a cohort of patients with anal cancer, treated with radical radiotherapy (RT) or CRT. The gene discussed is CDKN2A; the disease is anal carcinoma.